Document:

Exhibit
10.1

 

SECURITIES
PURCHASE AGREEMENT

 

THIS
SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of June 24, 2020, by and among Save Foods, Inc.,
a Delaware corporation (the “Company”) and ___________ (The “Investor”). This SPA is replacing
a CLA signed with the investor on _________.

 

WHEREAS,
the Company desires to issue and sell to the Investor, and the Investor desire to purchase from the Company, upon the terms and
conditions stated in this Agreement, for an aggregate purchase price of up to ________ (the “Purchase Price”),
______ units at a price of $1.09 (the “Units”), each Unit consists of (i) one share of Common Stock (the “Purchased
Shares”); and (ii) one warrant to purchase one share of Common Stock with an exercise price of $1.20 (the “Warrants”),
in the form attached hereto as Appendix A (collectively the “Warrants”, and together with the Purchased
Shares, the “Purchased Securities”), on the terms and conditions set forth in the Warrants; and

 

WHEREAS,
the Investor desire to purchase and the Company desires to issue and sell to the Investor the Securities pursuant to the terms
and conditions more fully set forth in this Agreement. The legend on the stocks will include the OID – January 6 2020.

 

NOW,
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.
PURCHASE AND SALE OF SECURITIES.

 

1.1
Sale and Issuance of Securities. Subject to the satisfaction of certain closing conditions set forth in Sections 4 and
5 hereof at the Closing (as defined below), the Company shall issue and sell to the Investor, and such Investor shall purchase,
severally and not jointly, from the Company , an aggregate of 49,541 Units at a purchase price of US$1.09 per each Unit.

 

1.2
Closing. The consummation of the transactions contemplated hereby, including the purchase and sale of the Purchased Securities
(the “Closing”) shall take place remotely via the exchange of documents and signatures, on June 24, 2020,
with the OID January 6 2020 or at such other time and place as the Company and the Investor mutually agree upon (such designated
time and place, the “Closing Date”). The Closing shall be subject to the conditions of Section 4 and 5 below,
which conditions shall be deemed to take place simultaneously and no transaction described in such sections shall be deemed to
have been completed or any document delivered until all such transactions have been completed and all such required documents
delivered.

 

1.3
Closing Deliverables.

 

(a)
At the Closing, the Company shall deliver to the Investor:

 

(i)
Book-entry confirmations representing respective Purchased Shares issued to each Investor at the Closing in the name of each of
such Investor.

 

(ii)
The Warrants issued to each Investor at the Closing in the name of each of such Investor; and

 

1.4
Purchase Price. Upon the execution of this Agreement, each Investor shall, severally and not jointly, transfer to the Company,
its respective portion of the Purchase Price by wire transfer of immediately available funds according to the wire instructions
attached hereto as Schedule 1.5.

 

2.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The
Company hereby represents and warrants to each Investor that, the following representations are true, correct and complete as
of the date hereof and as of the Closing (as if made on the Closing Date); except, in each case, as to such representations and
warranties that address matters as of a particular date, which are true, correct and complete only as of such date. The Disclosure
Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained
in this Section ‎2, and the information set forth in any one in any section or subsection of the Disclosure Schedule shall
apply to and qualify (a) the representation and warranty set forth in this Agreement to which it corresponds, and (b) whether
or not an explicit reference or cross-reference is made, each other representation and warranty set forth in this Agreement for
which it is reasonably apparent on its face that such information is relevant to such other section.

 

    	 

    	 

    

 

In
this Agreement, “Material Adverse Effect” means a material and adverse effect on the assets, properties, conditions
(financial or otherwise), operating results or business of the Company, as currently conducted.

 

2.1
Subsidiary. The Company wholly-owns Save Foods Ltd., an Israeli company (the “Subsidiary”), and as of
the date of the Agreement, the Subsidiary is the only subsidiary of the Company. The Company owns, directly , all of the capital
stock or other equity interests of the Subsidiary free and clear of any lien, charge, pledge, security interest, encumbrance,
right of first refusal, preemptive right or other restriction, and all of the issued and outstanding share capital of the Subsidiary
is validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

 

2.2
Organization. The Company and the Subsidiary are each an entity duly incorporated or otherwise organized, validly existing
and in good standing (if applicable in such jurisdiction) under the laws of the jurisdiction of its incorporation or organization,
with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.
Neither the Company nor the Subsidiary is in violation nor default of any of the provisions of its respective certificate of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiary is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a Material Adverse Effect on the legality, validity
or enforceability of any Transaction Document, (ii) a Material Adverse Effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiary, taken as a whole, or (iii) a Material Adverse
Effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or qualification.

 

2.3
Capitalization.

 

(a)
The authorized share capital of the Company will be on or immediately following to the Closing, as set forth in the Company’s
Certificate of Incorporation (the “COI”), and such number of Common Stock as set forth in the Capitalization
Table are or shall be (immediately following the Closing) issued and outstanding, which shall reflect as of the date hereof, he
number of shares of Common Stock issued to Investor pursuant to the Agreement,

 

(b)
The issued and outstanding shares of the Company were duly and validly authorized and issued, fully paid and non-assessable, and
offered and issued in compliance with the provisions of the COI as in effect at the time of each such issuance and in compliance
with all applicable corporate and securities laws.

 

(c)
Immediately prior to the Closing, no shares, options, warrants, rights (including conversion, preemptive rights, rights of first
refusal or similar rights) or agreements for the purchase from the Company of any of its stock capital, or any securities convertible
into or exchangeable for stock of the Company shall be outstanding,

 

(d)
Immediately prior to the Closing, no option, security or other equity award convertible or exercisable into stock of the Company
shall contain a provision for acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting provisions
or other terms of such option,

 

(e)
The Company has not declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or
series of its stock capital.

 

    	 

    	 

    

 

2.4
Authorization. All corporate action on the part of the Company, its directors and shareholders, necessary for the authorization,
execution and delivery of this Agreement and the other agreements, instruments or documents entered into in connection with this
Agreement and to which the Company is a party (collectively, the “Transaction Documents”) and for the performance
of all obligations of the Company under the Transaction Documents in accordance with their terms has been taken or will be taken
prior to the Closing. The Transaction Documents, when executed and delivered by the Company, and assuming the due authorization,
execution and delivery by the other parties hereto and thereto, constitute valid and binding obligations of the Company, enforceable
against the Company in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’
rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other
equitable remedies.

 

2.5
Valid Issuance. The Purchased Securities being or that may be issued to the Investor hereunder, when issued, sold and delivered
in accordance with the terms of this Agreement for the consideration expressed herein, shall be duly and validly issued, fully
paid, and non-assessable, issued in compliance with all applicable state securities laws, and free and clear of liens, pledges,
charges, encumbrances or other restrictions on transfer of any kind (including, without limitation, preemptive rights), other
than restrictions on transfer under this Agreement, the COI, the Company’s currently effective Bylaws (the “Bylaws”)
and under applicable securities laws and other than liens or encumbrances created by or imposed on each Investor as to itself.
The rights, privileges and preferences of the Purchased Securities are as stated in the COI and Bylaws, as may be amended from
time to time in accordance with its terms.

 

2.6
No Conflict; Consents. The execution, delivery and performance by the Company of this Agreement and the other Transaction
Documents to which it is a party, the issuance and sale of the Purchased Securities and the consummation by it of the transactions
contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of the COI or Bylaws or other
organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time
or both would become a default) under, result in the creation of any lien, charge, pledge, security interest, encumbrance, right
of first refusal, preemptive right or other restriction, upon any of the properties or assets of the Company, or give to others
any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company debt or otherwise) or other understanding to which the Company
is a party or by which any property or asset of the Company is bound or affected, or (iii) subject to the Required Approvals,
conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company is bound or affected; except in the case of each of clauses (ii) and (iii), such
as could not have or reasonably be expected to result in a Material Adverse Effect.

 

2.7
SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) since the Company’s registration statement on Form 10 was determined effective (collectively, the “SEC
Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports
prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects
with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules
and regulations of the U.S. Securities and Exchange Commission (the “Commission”) with respect thereto as in
effect at the time of filing. Such financial statements have been prepared in accordance with Generally Accepted Accounting Principles
in the U.S. (“US GAAP”), except as may be otherwise specified in such financial statements or the notes thereto
and except that unaudited financial statements may not contain all footnotes required by US GAAP, and fairly present in all material
respects the financial position of the Company as of and for the dates thereof and the results of operations and cash flows for
the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

    	 

    	 

    

 

2.8
Continued Quotation. The Company is, and has no reason to believe that it will not in the foreseeable future continue to
be, in compliance with all such quotation and maintenance requirements of the “Pink Sheets” published and maintained
by OTC Markets Group, Inc., and shall make commercial best efforts to maintain such compliance.

 

2.9
Financial Statements; No Undisclosed Liabilities.

 

(a)
The Company has no liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course
of business, which, individually and in the aggregate, do not exceed US$200,000; (ii) obligations under contracts and commitments
incurred in the ordinary course of business including debt of the Subsidiary to the parent company of the Company in the principal
amount of US$500,000; (iii) liabilities and obligations of a type or nature not required under GAAP to be reflected in its financial
statements, which, individually and in the aggregate do not exceed US$100,000;

 

(b)
The Company is not a guarantor or indemnitor of any debt or obligation of another, nor has the Company given any loan, security
or otherwise agreed to become liable for any obligation of any person. No person has given any guarantee of, or security for,
any obligation of the Company. The Company did not extend any loans or advances to any person, other than advances for expenses
to its employees in the ordinary course of business.

 

2.10
Assets and Properties. Both the Company and the Subsidiary have good and marketable title to all of the tangible or personal
properties and assets owned by the Company and the Subsidiary, which are material to the business of the Company or the Subsidiary
as currently conducted, and such properties and assets are free and clear of all mortgages, deeds of trust, liens, pledges, charges,
security interests, conditional sale agreement, loans and encumbrances, except for statutory liens for the payment of current
taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and do not materially
impair the Company’s or the Subsidiary’s ownership or use of such property or assets. With respect to the tangible
property and assets it leases, the Company and the Subsidiary are in compliance in all material respects with such leases and,
to its knowledge, holds a valid leasehold or license interest free of any liens, pledges, charges, security interest, claims or
encumbrances, other than those of the lessors of such property or assets. The Company and the Subsidiary do not own any real property.

 

2.11
Intellectual Property. The Company and the Subsidiary have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property
rights and similar rights for use in connection with their respective businesses and which the failure to so have could have a
Material Adverse Effect (collectively, the “Intellectual Property Rights”). Neither the Company nor the Subsidiary
have received a notice (written or otherwise) that any of, the material Intellectual Property Rights has expired, terminated or
been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither
the Company nor the Subsidiary have received, since Jan 1, 2019, a written notice of a claim or otherwise has any knowledge that
the Intellectual Property Rights violate or infringe (and will not infringe) upon the rights of any Person, except as could not
have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and the Subsidiary have taken reasonable security measures to protect the secrecy, confidentiality and value of all of
their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it or the Subsidiary from having
valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that either it or the Subsidiary
lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct
its business. For purposes of this Section, “knowledge”, including the phrase “to the Company’s knowledge”
(or similar phrases), when used in this Section 2.11 (Intellectual Property) shall mean the actual knowledge of the Company,
without conducting any patent search, freedom to operate, infringement, or any similar search.

 

    	 

    	 

    

 

2.12
Labor Matters.

 

(a)
The Company and the Subsidiary have complied, in all material respects, with all applicable employment laws, policies, procedures
and agreements relating to employment, and terms and conditions of employment. The Company and the Subsidiary have paid in full
to all of its respective employees and consultants all wages, salaries, commissions, bonuses, benefits and other compensation
due and payable to such employees or consultants on or prior to the date of this Agreement. The Company and the Subsidiary have
complied in all material respects with the applicable laws relating to the proper withholding and remittance to the proper tax
and other authorities of all sums required to be withheld from employees or persons deemed to be employees under applicable laws.
To the Company’s knowledge, all persons classified by the Company or the Subsidiary as consultants or contractors thereof
are correctly classified as such and not as employees for any purpose. The Company’s and the Subsidiary’s liability
for any obligations to pay any amount of severance payment, pension, accrued vacation, and other social benefits and contributions,
under applicable law or contract, or any other payment of substantially the same nature, is fully funded by deposit of funds in
severance funds, pension funds, managers insurance policies or provident funds (and if not required to be so funded) adequate
provisions have been made in the Company’s Financial Statements.

 

(b)
Neither the Company nor the Subsidiary is a party to, bound by or subject to, and no employee of the Company or the Subsidiary
benefits from, any collective bargaining agreement, collective labor agreement, extension orders (tzavei harchava) (other
than extension orders that apply to all employees in Israel generally), or other contract or arrangement with a labor union, trade
union or other organization or body, to provide benefits or working conditions beyond the minimum benefits and working conditions
required by applicable law. No labor union has requested or has sought to represent any of the employees, representatives or agents
of the Company or the Subsidiary, nor is the Company or the Subsidiary aware of any labor organization activity involving its
employees. There is no strike or other labor dispute involving the Company or the Subsidiary pending or, to the Company’s
knowledge, threatened.

 

2.13
Taxes. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in
a Material Adverse Effect, the Company and the Subsidiary each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is
subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined
to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the
payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. Except
as disclosed in SEC Reports, there are no unpaid taxes in any material amount claimed to be due by the taxing authority of any
jurisdiction, and neither the officers of the Company nor the Subsidiary know of no basis for any such claim.

 

2.14
Governmental Grants. Neither the Company nor the Subsidiary have applied, obtained or received any grant, loan, incentives,
benefits (including tax benefits), subsidies or other assistance from any governmental or regulatory authority or any agency,
or any international or bilateral fund, institute or organization or public entities or authorities.

 

2.15
Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or, to the Company’s knowledge,
investigation pending, or, to the Company’s knowledge, currently threatened in writing against the Company or the Subsidiary,
any of its properties, or any officer, director or employee of the Company or the Subsidiary, including, without limitation, arising
out of their employment or board relationship with the Company or the Subsidiary or in their capacity as such, or that questions
the validity of the Transaction Documents or the right of the Company to enter into them, or to consummate the transactions contemplated
by the Transaction Documents.

 

2.16
Insurance. The Company and the Subsidiary are covered by insurance with respect to its properties and business.

 

2.17
Disclosure. No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure Schedule,
and no certificate furnished or to be furnished to Investor at the Closing contains any untrue statement of a material fact or,
to the Company’s knowledge, omits to state a material fact necessary in order to make the statements contained herein or
therein not misleading in light of the circumstances under which they were made.

 

    	 

    	 

    

 

3.
REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.

 

Each
of the Investor, severally and not jointly, hereby represents and warrants, with respect to itself only, that the following representations
are true, correct and complete as of the date hereof and as of the Closing (as if made on the Closing Date); except, in each case,
as to such representations and warranties that address matters as of a particular date, which are given only as of such date:

 

3.1
Authorization; Organization. The Investor is duly organized, validly existing and, if applicable, in good standing under
the laws of the jurisdiction in which it has been incorporated and has full power and authority to enter into the Transaction
Documents. The Transaction Documents to which the Investor is a party, when executed and delivered by the Investor, and assuming
the due authorization, execution and delivery by the other parties hereto and thereto, constitute valid and binding obligations
of the Investor, enforceable against the Investor in accordance with their respective terms, except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or
affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies, and (iii) to the extent the indemnification provisions contained
herein, as may be limited by applicable securities laws.

 

3.2
No Conflict; Consents. The execution, delivery and performance by the Investor of the Transaction Documents to which it
is a party and the consummation of the transactions contemplated by such Transaction Documents do not and will not (a) result
in any conflict with, or a breach or violation, with or without the passage of time and giving of notice, of any of the terms,
conditions or provisions of, or give rise to rights to others (including rights of termination, cancellation or acceleration)
under: (i) the governing documents of the Investor; (ii) any judgment, injunction, order, writ, decree or ruling of any court
or governmental authority, domestic or foreign, to which the Investor is subject; (iii) any material contract or agreement, lease,
license or commitment to which the Investor is a party or by which it is bound; (iv) any applicable law; or (b) require the consent,
approval or authorization of, registration, qualification or filing with, or notice to any person or any federal, state, local
or foreign governmental authority or regulatory authority or agency, on the part of the Investor, which has not heretofore been
obtained or made or will be obtained or made prior to Closing.

 

3.3
Purchase Entirely for Own Account. The Purchased Securities will be acquired for investment for the Investor’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and the Investor has
no present intention of selling, granting any participation in, or otherwise distributing the same. The Investor does not presently
have any contract, undertaking, agreement or arrangement to sell, transfer or grant participation rights to any person with respect
to any of the Purchased Securities. The Investor has not been formed for the specific purpose of acquiring the Purchased Securities.

 

3.4
Disclosure of Information. The Investor has had an opportunity to discuss the Company’s business, operations, properties,
prospects, technology, plans, management, financial affairs and the terms and conditions of the offering of the Purchased Securities
with the Company’s management and has had an opportunity to review the Company’s facilities. The foregoing, however,
does not limit, modify or qualify the representations and warranties of the Company in Section ‎2 of this Agreement or the
right of the Investor to rely thereon. The Investor acknowledges that any projections provided (if any) by the Company are uncertain
in nature, and that some or all of the assumptions underlying such projections may not materialize or will vary significantly
from actual results.

 

3.5
Investment Experience; Accredited Investor; Non-U.S. Person. The Investor is an investor in securities of companies in
the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has
such knowledge and experience in financial or business matters that it is capable of evaluating and understanding the merits and
risks of the investment in the Purchased Securities. The Investor is either (i) an accredited investor as defined in Rule 501(a)
of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), or (ii) a
Non U.S. Person as defined under Regulation S promulgated under the Securities Act. To the extent that the Investor is a non U.S.
Person, such Investor (x) is not acquiring Purchased Securities for the account or benefit of any U.S. Person, (y) is not, at
the time of execution of this Agreement, and will not be, at the time of the Closing, in the United States and (z) is not a “distributor”
(as defined in Regulation S promulgated under the Securities Act).

 

    	 

    	 

    

 

3.6
Restricted Securities. The Purchased Securities have not been and will not be registered under the Securities Act or any
state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state
securities laws or unless an exemption from such registration requirements is available. Investor is aware that, except as set
forth herein, the Company is under no obligation to effect any such registration or to file for or comply with any exemption from
registration. The sale and issuance of the Purchased Securities have not been registered under the Securities Act by reason of
a specific exemption from registration which depends upon, among other things, the accuracy of the Investor’s representations
as expressed herein.

 

3.7
Legends. The Purchased Securities, and (if applicable) any securities issued in respect of or exchange for the foregoing
may be notated with the following or a similar legend as well as other legends as may be required by applicable securities laws:
“THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO TRANSFER OF SUCH SHARES MAY BE EFFECTED WITHOUT
AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

3.8
Exculpation among Investor. The Investor is not relying upon any other Investor in making its investment or decision to
invest in the Company. Neither of the other Investor nor the respective controlling persons, officers, directors, partners, agents,
employees or legal or other advisors of any such other Investor shall be liable to the Investor for any action heretofore taken
or omitted to be taken by any of them in connection with the purchase of the Purchased Securities.

 

4.
CONDITIONS OF INVESTOR’ OBLIGATIONS AT CLOSING.

 

The
obligations of each Investor to purchase the Purchased Securities at the Closing are subject to the fulfillment on or before the
Closing of each of the following conditions, unless otherwise waived in writing by the Majority Investor:

 

4.1
Representations and Warranties. The representations and warranties of the Company in Section 2 of this Agreement shall
have been true in all respects on and as if made as of the Closing.

 

4.2
Performance. The Company shall have performed and complied, in all respects, with all agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by it on or before the Closing.

 

4.3
Delivery of Documents. All of the documents to be delivered by the Company pursuant to Section 1.5, shall have been in
a form as attached to this Agreement, or, if not attached, in a form and substance satisfactory to the Investor and shall have
been delivered to the Investor.

 

5.
CONDITIONS OF THE COMPANY’S OBLIGATIONS AT CLOSING.

 

The
obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing, of each
of the following conditions, unless otherwise waived in writing by the Company:

 

5.1
Representations and Warranties. The representations and warranties contained in Section ‎3 shall have been true in
all respects on and as if made as of the Closing.

 

5.2
Performance. Each of the Investor shall have performed and complied, in all respects, with all agreements, obligations
and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing.

 

6.
AFFIRMATIVE COVENANTS BY THE COMPANY.

 

6.1
Use of Proceeds. The Company will use the Purchase Price for general working capital purposes.

 

6.2
Conduct of the Business between Signing and Closing. Except as otherwise expressly provided by this Agreement or with the
prior written consent of each of the Investor individually (which consent shall not be unreasonably withheld or delayed), the
Company shall (i) conduct its business in the ordinary course of business, consistent with prior practice; (ii) comply with legal
requirements applicable to the operation of its business and pay applicable taxes as due; (iii) maintain its books, accounts and
records in the ordinary course of business; and (iv) not take any other action that would result in a breach of any of the representations,
warranties or covenants made by the Company in this Agreement or that would adversely affect its ability to consummate the transactions
contemplated by this Agreement.

 

    	 

    	 

    

 

7.
INDEMNIFICATION.

 

7.1
Effectiveness; Survival.

 

(a)
Each Investor has the right to fully rely upon all representations, warranties and covenants of the Company, for which the Company
shall be held responsible (the “Indemnitor”) contained in or made pursuant to this Agreement and in the schedules
attached hereto. Unless otherwise set forth in this Agreement, the representations and warranties of the Company contained in
or made pursuant to this Agreement shall in no way be affected by any investigation or knowledge of the subject matter thereof
made by or on behalf of any Investor.

 

(b)
The representations and warranties of the Company contained in or made pursuant to this Agreement shall survive the execution
and delivery of this Agreement and the Closing, until (1) in case of Section 2.11 (Intellectual Property), until the 30th
months anniversary of the Closing Date; (2) in case of Sections 2.2 (Organization), 2.4 (Authorization) and
2.6 (No Conflict; Consents), until the expiration of the applicable statute of limitation period; and (3) other than as
set forth in clause (1) above, the 24th months anniversary of the Closing Date; in each case, with respect to any theretofore
un-asserted claims as set forth in clause (d) below;

 

(c)
In respect to Section 7.1(b) above, no limitation shall apply to breach of any representation or warranty which constitutes fraud
or willful misrepresentation by the Company (“Fraud”). The applicable survival period shall be referred to,
as applicable, as the “Claims Period”.

 

(d)
Except for Fraud, the Company shall have any liability with respect to any breach of representation and warranty, unless a claim
is made hereunder prior to the expiration of the Claims Period for such representation and warranty, in which case such representation
and warranty shall survive as to that claim until the claim has been finally resolved.

 

(e)
It is the intention of the parties hereto that the Claims Periods supersede any statute of limitations applicable to the representations
and warranties, and this Section ‎7.1 constitutes a separate written legally binding agreement among the parties hereto
in accordance with the provisions of Section 19 of the Israeli Limitation Law, 1958.

 

7.2
Indemnification.

 

(a)
Indemnifiable Losses. The Indemnitor shall indemnify each Investor (including its shareholders, limited and general partners
directors and officers) (each, an “Indemnitee”) against, and hold each Indemnitee harmless from all claims,
actions, suits, settlements, damages, expenses (including, reasonable legal costs and expenses), losses, or costs sustained or
incurred by such Indemnitees (collectively, “Losses”) resulting from, or arising out of, a breach or misrepresentations
of any the Indemnitor’s representations, warranties or covenants made in this Agreement, subject to the limitations in this
Section ‎7.

 

(b)
Limitations. The Indemnitee’s right for indemnification hereunder is subject to the following conditions and limitations,
notwithstanding anything to the contrary in this Agreement, but in to any other limitation or condition contained herein; provided,
however, no limitation shall apply to Fraud:

 

(i)
Other than in respect of the Fundamental Representations, no Indemnitor shall be liable for any Loss, unless and until the aggregate
of Losses equal or exceeds US$100,000, in which case indemnification shall be made from the first dollar amount.

 

(ii)
The Indemnitor’s liability shall be limited with respect to each Investor to the respective portion of Purchase Price of
such Investor at the Closing and each Indemnitee shall be entitled to receive a pro rata share of the indemnifiable Loss, based
on the respective portion of such Investor of the Purchase Price as of the Closing.

 

    	 

    	 

    

 

(c)
Claims Notice; Third Party Claims. In the event that an Indemnitee wishes to assert a claim for indemnification hereunder
it shall give the Indemnitor a prompt written notice thereof (a “Claims Notice”), which shall describe in reasonable
detail the facts and circumstances upon which the asserted claim for indemnification is based and thereafter keep the Indemnitor
informed, in all material respects, with respect thereto. In the event that such Claims Notice results from a third party claim
against the Indemnitee, such Indemnitee shall promptly upon becoming aware of the commencement of proceedings by such third party
provide the Indemnitor with the Claims Notice and the Indemnitor shall have the right to assume the defense thereof (at Indemnitor’s
expense) with counsel mutually satisfactory to the parties; provided, however, that the Indemnitees shall have the right
to retain their own counsel, at the reasonable expense of the Indemnitor, and within the indemnification limitations herein, if
representation of all parties by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing
interests between the parties in such proceeding. Failure of the Indemnitees to give prompt notice or to keep it informed, as
provided herein, shall not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor
is actually and materially prejudiced by such failure. The Indemnitor shall not be liable nor shall it be required to indemnify
or hold harmless the Indemnitee in connection with any settlement effected without its consent in writing, which shall not be
unreasonably withheld or delayed.

 

(d)
Sole Remedy. The indemnification provided by the Indemnitor hereunder and the enforcement of such indemnification shall
be the exclusive remedy available to the Indemnitees under this Agreement, other than for Fraud; provided that this provision
does not limit the right to seek specific performance, a restraining order or injunctive relief with respect to any provision
of this Agreement.

 

8.
MISCELLANEOUS.

 

8.1
Further Assurances. Each of the parties hereto shall perform such further acts and execute such further documents as may
reasonably be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties
as reflected thereby.

 

8.2
Entire Agreement. This Agreement (including the exhibits and schedules hereto) and the other Transaction Documents constitute
the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and supersede all
prior agreements and understandings, both written and oral, among any of the parties hereto, with respect to the subject matter
hereof (with no concession being made as to the existence of any such prior agreements or understandings).

 

8.3
Amendment; Waiver. Except as explicitly set forth herein, any term of this Agreement may be amended only with the written
consent of both the Company and the Majority Investor, provided that any amendment amending an Investor’s respective portion
of the Purchase Price to be invested at the Closing, or any amendment that has a disproportionate and adverse effect on specific
Investor(s) (as compared to other Investor), shall require also such specific Investor’s prior written consent. The observance
of any term hereof may be waived (either prospectively or retroactively and either generally or in a particular instance) only
by the prior written consent of the party against which enforcement of such waiver shall be sought (and in case enforcement will
be sought against the Investor, of the Majority Investor). Any amendment or waiver effected in accordance with this Section ‎8.3
shall be binding upon the Investor and each transferee of the Purchased Securities, each future holder of all such securities
and the Company.

 

8.4
Assignment; Successors and Assigns. None of the rights, privileges or obligations set forth in, arising under, or created
by this Agreement may be assigned or transferred by an Investor, without the prior written consent of the Company. Nothing in
this Agreement, express or implied, is intended to confer upon any party other than the parties hereto any rights, remedies, obligations,
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

8.5
Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with to the laws of the State
of Israel, disregarding its conflict of laws rules. Any dispute arising under or in relation to this Agreement shall be resolved
exclusively in the competent court located in Tel Aviv-Jaffa, Israel and each of the parties hereby irrevocably submits to the
exclusive jurisdiction of such court. Each of the parties hereto (i) consents to submit itself to the exclusive jurisdiction of
the abovementioned courts in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement,
(ii) agrees that it shall not attempt to deny or defeat such jurisdiction by motion or other request for leave from the abovementioned
court, (iii) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement
in any court other than the abovementioned court, and (iv) irrevocably consents to service of process in the manner provided by
Section ‎8.6 or as otherwise provided by applicable law.

 

    	 

    	 

    

 

8.6
Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt, or (i) when delivered, if sent by personal delivery to the party
to be notified, (ii) when sent, if sent by electronic mail or facsimile (with electronic conformation of delivery) on a business
day and during normal business hours of the recipient, and otherwise on the first business day in the place of recipient, (iii)
five (5) business days after having been sent, if sent by registered or certified mail, return receipt requested, postage prepaid,
or (iv) one (1) business day after deposit with an internationally recognized overnight courier, freight prepaid, specifying next
business day delivery, with written confirmation of receipt. All communications shall be sent to the respective parties at their
address or contact details as set forth below, or to such address or contact details as subsequently modified by written notice
given in accordance with this Section 8.6 or, in the case of the Investor, as used for purposes of sending shareholders’
notices by the Company.

 

	If
    to the Company:	Habarzel 7, Tel Aviv, Israel 6971011 
	 	Attention:	Dan
    Sztybel
	 	Telephone:	+972-72-2116144
	 	E-mail:	dan@savefoods.co
	 	 	 
	 	with a mandatory copy to (which shall not constitute a notice):
	 	 	 
	 	Meitar Law Offices

16 Abba Hillel St., Ramat-Gan, Israel

	 	Attention:	Dr.
    Shachar Hadar, Adv.
	 	Telephone:	+972-3-6103961
	 	E-mail:	shacharh@meitar.com
	 	 	 
	If
    to the Investor:	as set forth on the signature page hereto/Exhibit A

 

8.7
Delays or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing
to any party to this Agreement upon any breach or default of any other party under this Agreement, shall impair any such right,
power or remedy of such non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed
a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set
forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement,
shall be cumulative and not alternative.

 

8.8
Interpretation. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. The words “include”, “includes” and “including”
shall be deemed to be followed by the phrase “without limitation”. Unless the context requires otherwise, the words
“herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer
to this Agreement in its entirety, and not to any particular provision hereof, and all references herein to Sections shall be
construed to refer to Sections to this Agreement. Reference to “governmental authorities” (or similar terms) shall
include any: (a) nation, principality, state, commonwealth, territory, county, municipality, district or other jurisdiction of
any nature, (b) federal, state, local, municipal, foreign or other government, (c) governmental, quasi-governmental or regulatory
body of any nature, including any governmental division, subdivision, department, agency, bureau, branch, office, commission,
council, board, instrumentality, organization, unit, or body, or (d) court, public or private arbitrator or other public tribunal.
Reference to a “person” shall mean any individual, corporation, partnership, limited liability company, firm, joint
venture, association, joint-stock company, trust, estate, unincorporated organization, governmental authority or other entity,
including, any party to this Agreement. Any reference to a “day” or a number of days (without explicit reference to
“business days”) shall be interpreted as a reference to a calendar day or number of calendar days, and if any action
is to be taken or given on or by a particular calendar day, and such calendar day is not a business day, then such action may
be deferred until the first business day thereafter (where “business day” shall mean any day on which banking institutions
in Tel-Aviv-Jaffa, Israel are generally open to the public for conducting business and are not required by law to close).

 

8.9
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of the Agreement shall be enforceable in accordance with its terms and interpreted
so as to give effect, to the fullest extent consistent with and permitted by applicable law, to the meaning and intention of the
excluded provision.

 

8.10
Counterparts. This Agreement and any Transaction Document may be executed in one or more counterparts, all of which together
shall constitute one and the same instrument, binding and enforceable against the parties so executing the same; it being understood
that all parties need not sign the same counterpart. Counterparts may also be delivered by facsimile or email transmission (in
pdf format or the like, or signed with docusign, e-sign or any similar form of signature by electronic means) and any counterpart
so delivered shall be sufficient to bind the parties to this Agreement or any other Transaction Document, as an original.

 

-
Signature Pages Follow -

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this SECURITIES PURCHASE AGREEMENT to be executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	SAVE
    FOODS, INC.
	 	 	 
	 	By:	    
	 	Name:	Dan
    Sztybel
	 	Title:	Chief
    Executive Officer

 

[Company
Signature Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this SECURITIES PURCHASE AGREEMENT as of the date first written above.

 

INVESTOR:

 

Signature:
__________________________

 

Name:

Title:

 

Investment
Amount:

 

[Investor
Signature Page to Securities Purchase Agreement]Exhibit
10.2

 

83NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
SECURED BY SUCH SECURITIES.

 

WARRANT
TO PURCHASE SHARES OF COMMON STOCK

OF

SAVE
FOODS, INC.

(the
“Corporation”)

 

Number
of Shares of Common Stock of the Corporation, par value $0.0001 each (the “Common Stock”): _____________

 

Issue
Date: ________, 2020

Initial
Exercise Date: _________, 2020.

 

This
warrant to purchase shares of Common Stock (the “Warrant”) certifies that, for value received, ________________
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after _________ , 2020 (the “Initial Exercise Date”), and on or prior to the close
of business 36 (thirty-six) months following the Issue Date (the “Termination Date”), provided that, if such
date is not a Trading Day, the Termination Date should be the immediate following Trading Day but not thereafter, to subscribe
for and purchase from the Corporation, up to ________ shares of Common Stock (the “Warrant Shares”). The purchase
price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Securities
Purchase Agreement (the “Purchase Agreement”), dated ___________, 2020, among the Corporation and the Holder,
as applicable.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the rights represented by this Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Corporation (or such other
office or agency that the Corporation may designate by notice in writing to the registered Holder at the address of the Holder
appearing on the books of the Corporation) of a duly executed facsimile copy or PDF copy submitted by electronic mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier
of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Corporation until the Holder has purchased all of the Warrant Shares available hereunder and the
Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Corporation for cancellation
within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Corporation. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Corporation shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Corporation shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt
of such notice. The Holder, by acceptance of this Warrant, acknowledges and agrees that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.

 

    	 

     

    

 

In
no event will the Corporation be required to net cash settle a Warrant exercise.

 

b)
Exercise Price. The exercise price per Share under this Warrant shall be $1.20, subject to adjustment hereunder (the “Exercise
Price”).

 

c)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Corporation shall cause its transfer agent (the “Transfer Agent”)
to issue the Warrant Shares, and credit the account of the Holder or (B) the Warrant Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered
in the name of the Holder, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise, by the date that is the earlier of (i) two (2) Trading Days and (ii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Corporation of the Notice of Exercise (such
date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed
for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been
exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price is
received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. As used herein, “Standard Settlement Period” means the
standard settlement period, expressed in a number of Trading Days, on the Corporation’s primary Trading Market with respect
to the Shares as in effect on the date of delivery of the Notice of Exercise.

 

    	 

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Corporation shall, at the
request of the Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to
the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant,
which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Corporation fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(c)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.
No Fractional Warrant Shares or Scrip. No fractional Warrant Shares shall be issued upon the exercise of this Warrant.
As to any fraction of a Share that the Holder would otherwise be entitled to purchase upon such exercise, the Corporation shall
be entitled to round down such to the next whole Share.

 

v.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of Warrant Shares, all of which taxes and expenses shall be paid by
the Corporation, and such Warrant Shares shall be issued in the name of the Holder. The Corporation shall pay all applicable fees
and expenses of the Transfer Agent in connection with the issuance of the Warrant Shares hereunder.

 

The
Holder is aware and agree that any tax consequences arising from the grant or exercise of any Warrant from the payment for Warrant
Shares covered thereby or from any other event or act (of the Corporation and/or its Affiliates or the Holder), hereunder, shall
be borne solely by the Holder. The Corporation and/or its Affiliates shall withhold taxes according to the requirements under
the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Holder hereby accept to indemnify
the Corporation and/or its Affiliates and hold them harmless against and from any and all liability for any such tax or interest
or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any
such tax from any payment made to you.

 

The
Holder will not be entitled to receive from the Corporation any Warrant Shares allocated or issued upon the exercise of the Warrant
prior to the full payments of any tax liabilities arising from the Warrants, which were granted to the Holder and/or the Warrant
Shares issued upon the exercise of the Warrants. For the avoidance of doubt, the Corporation shall not be required to release
any share to the Holder until all payments required to be made by the Holder have been fully satisfied.

 

    	 

     

    

 

vi.
Closing of Books. The Corporation will not close its shareholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

Section
3. Certain Adjustments.

 

a)
Share Dividends and Splits. If the Corporation, at any time while this Warrant is outstanding: (i) pays a share dividend
or otherwise makes a distribution or distributions on its Shares or any other equity or equity equivalent securities payable in
Shares (which, for avoidance of doubt, shall not include any Shares issued by the Corporation upon exercise of this Warrant),
as applicable, (ii) subdivides outstanding Shares into a larger number of Shares, as applicable, (iii) combines (including by
way of reverse share split) outstanding Shares into a smaller number of Shares, as applicable, or (iv) issues by reclassification
of Shares, or any shares of capital stock of the Corporation, as applicable, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of Shares, (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of Shares, outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after
the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.

 

    	 

     

    

 

b)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Corporation, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the
Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Shares
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Shares, (iv) the Corporation, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Shares or any compulsory share exchange pursuant to which the
Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or
indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires more than 50% of the outstanding Shares (not including Shares held
by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares of capital stock
of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number
of Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
amount of Alternate Consideration issuable in respect of one Share, in such Fundamental Transaction, and the Corporation shall
apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Shares are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Fundamental Transaction. The Corporation shall cause any successor entity
in a Fundamental Transaction in which the Corporation is not the survivor (the “Successor Entity”) to assume
in writing all of the obligations of the Corporation under this Warrant and the other Transaction Documents in accordance with
the provisions of this Section 3(b) pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the
Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the Shares represented by each Warrant Share acquirable and
receivable upon exercise of this Warrant prior to such Fundamental Transaction, and with an exercise price which applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the Shares pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant and the other Transaction Documents referring to the “Corporation” shall refer instead
to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of
the Corporation under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been
named as the Corporation herein.

 

c)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a Share,
as the case may be. For purposes of this Section 3, the number of Shares deemed to be issued and outstanding as of a given date
shall be the sum of the number of Shares (excluding treasury shares, if any) issued and outstanding.

 

    	 

     

    

 

d)
Notice to Holder. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Corporation
shall deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

Section
4. Transfer of Warrant.

 

a)
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are non-transferable.

 

b)
Warrant Register. The Corporation shall register this Warrant, upon records to be maintained by the Corporation for that
purpose (the “Warrant Register”), in the name of the record Holder hereof.

 

c)
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section
5. Miscellaneous.

 

a)
No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a shareholder of the Corporation prior to the exercise hereof as set forth in Section 2(c)(i).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Corporation covenants that upon receipt by the Corporation of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating
to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and
upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Corporation will make and deliver a new
Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c)
Fridays, Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

    	 

     

    

 

d)
Authorized Shares. The Corporation covenants that, during the period the Warrant is outstanding, it will reserve from its
authorized and unissued Shares a sufficient number of shares to provide for the issuance of the Warrant Shares and underlying
Shares upon the exercise of any purchase rights under this Warrant. The Corporation further covenants that its issuance of this
Warrant shall constitute full authority to its officers who are charged with the duty of issuing the Warrant Shares needed for
the Transfer Agent to issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Corporation
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the applicable Trading Market upon which the Shares may
be listed. The Corporation covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges
created by the Corporation in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the Purchase Agreement, as applicable.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of the
Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding
the fact that all rights hereunder terminate on the Termination Date, if the Corporation willfully and knowingly fails to comply
with any provision of this Warrant, which results in any material damages to the Holder, the Corporation shall pay to the Holder
such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’
fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
enforcing any of its rights, powers or remedies hereunder.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Corporation
shall be delivered in accordance with the notice provisions of the Purchase Agreement, as applicable.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Shares or as a shareholder of the Corporation, whether such liability is asserted
by the Corporation or by creditors of the Corporation.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Corporation agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

    	 

     

    

 

k)
Successors. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors of the Corporation and the successors of Holder.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Corporation
and the Holder.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	 

     

    

 

IN
WITNESS WHEREOF, the Corporation has caused this Warrant to be executed by its officer thereunto duly authorized as of the date
first above indicated.

 

	 	SAVE FOODS, INC.
	 	 	 
	 	By:	          
	 	Name:	 
	 	Title:	 

 

    	 

     

    

 

NOTICE
OF EXERCISE

 

To:
SAVE FOODS, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Corporation pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full in form of United States currency; or

 

(2)
Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

(3)
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

(4)
The Warrant Shares shall be delivered to the Investor

 

____________________________________

 

____________________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity:

 

________________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity:

 

________________________________________________________________________

 

Name
of Authorized Signatory: _____________________________________________________________________

 

Title
of Authorized Signatory: ______________________________________________________________________

 

Date:
_____________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]